[ Meet Robo ]
From the entire landscape to the opportunities that matter.
Robo bundles domain intelligence and purpose-built AI agents to execute the research and evaluation work the way you want, at a scale that wasn't possible until now.
[ Connected drug intelligence ]
Better evaluations start with better data.
The information needed to understand a drug program is scattered across clinical trials, publications, regulatory records, patents, company pipelines, and other sources.
The same program may appear under different names. Important evidence may sit in disconnected records. Critical relationships can be difficult to piece together.
Robo does that foundational work so your team and its AI agents can focus on evaluating the programs themselves.
- Clinical trials
- Publications
- Regulatory
- Patents
- Company pipelines
- Your notes
“Not just another database. A foundation built to turn drug information into evaluations your company can act on.”
One program, one connected record.
Robo reconciles drug names, development codes, and company identities to bring fragmented information together.
Evidence in context.
Clinical, scientific, regulatory, and commercial information is connected to the programs and companies it describes, rather than treated as isolated facts.
Structured for comparison.
Information from different sources is organized into consistent fields and relationships, making it possible to search, research, and evaluate programs at scale.
Research you can trace.
Evaluations are backed by supporting evidence and links to sources, so your team can understand and verify the findings.
[ Intelligence that stays current ]
It's not just what changed. It's what that change means.
A data feed can tell you that a company published new clinical results.
Robo can go further. By connecting new evidence to your existing evaluations, it helps you understand whether that development changes a program's relevance, competitive position, or fit with your strategy.
A competitor reports positive Phase 2 results for a metabolic disease program.
New efficacy data meets your predefined threshold. Two evaluation criteria have changed, increasing this program's relevance to your landscape.
Supporting evidence and assessment available for review.
[ Illustrative example ]
Less time reviewing every update. More time understanding the ones that matter.
[ Built on what you already know ]
Every evaluation adds to your company's understanding.
Drug evaluations shouldn't disappear into spreadsheets, presentations, or individual projects.
Robo keeps programs, research, supporting evidence, and evaluations connected in one workspace. Your team can revisit previous work, bring its own expertise into the process, and build on what it has already learned.
When a program comes up again, you're not starting from zero. You can see what was previously evaluated, understand the reasoning, and investigate what's changed.
And as your team evaluates more programs, it builds something increasingly valuable: its own informed view of the external drug landscape.
Your company's knowledge, put to work in every evaluation.
[ Purpose-built for pharma ]
One engine. Many ways to evaluate.
In-licensing and opportunity screening
Evaluate incoming and proactively sourced opportunities against your strategy. Identify the programs worth pursuing and understand why.
Therapeutic-area landscapes
Map the programs, companies, and competitive dynamics in an indication or modality. Keep the landscape current as new evidence and programs emerge.
Company screening
Research and compare potential partners or acquisition targets. Evaluate their pipelines, scientific positioning, and strategic fit.
Conference intelligence
Screen attending companies, drug programs, and scientific abstracts ahead of major conferences. Know what to investigate and who deserves a meeting.
Repurposing and target evaluation
Explore programs beyond their current indications. Research biological rationale, clinical evidence, and competitive opportunities across different applications.
[ Robo in practice ]
Real work, at a different scale.
Pharma teams are using Robo to take on evaluation work that would otherwise demand substantial manual effort.
Therapeutic-area landscapes
Build and maintain a structured view of the programs and companies in an area of interest.
Large-scale company screening
Research extensive lists of potential partners and narrow them into an actionable shortlist.
Partnering preparation
Evaluate companies and their pipelines before conferences and partnering events.
Scientific abstract screening
Research and triage new conference abstracts against specific scientific and commercial criteria.
Ongoing competitive evaluation
Track new programs and developments, and understand when the evidence changes an existing assessment.
